market access

News

NICE backs kidney cancer combination from Merck KGaA and Pfi...

NICE has said a combination of Merck KGaA’s Bavencio and Pfizer’s Inlyta should be available as a first line option for kidney cancer patients for NHS patients in England.

News

NICE backs NHS use for Astellas' Xospata after rethink

NICE has recommended regular NHS funding for Astellas’ Xospata (gilteritinib) monotherapy for certain adult patients with acute myeloid leukaemia

Partner Content

Windrose Consulting Group Managing Parners

Partner Content

Windrose Consulting Group acquires Parioforma

Windrose acquires Parioforma as part of growth strategy

News

All EU Flags in front of the European Parliament, Flags in front of the European Parliament, Strasbourg, Alsace, France

Survey shows patients wait six times longer than EU neighbou...

Patients in some European countries are waiting up to six times longer for access to medicines than their neighbours, according to a survey by Europe’s pharma trade body.

News

Germany first in EU to get Novartis' SMA gene therapy, costi...

Novartis is set to launch its one-off gene therapy Zolgensma for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) in Germany at the start of July priced at 1,945,000 euro

News